Company news
Noxopharm Ltd. (ASX:NOX) news
Noxopharm Ltd. news releases on 6ix. Latest, Jul 5, 2018: Pre-Clinical data confirms Radio-Enhancing potential
Press releases — page 5
Pre-Clinical data confirms Radio-Enhancing potential
July 4, 2018
End-of-Study Clinical Data shows benefit of NOX66
June 5, 2018
NOX to present at American Society of Clinical Oncology
May 21, 2018
NOX CEO interview on near complete NOX66 chemotherapy trial
May 3, 2018
NOX CEO interview on Radiotherapy Clinical Programs
April 27, 2018
St Vincents Hospital study passes first milestone
April 16, 2018
DARRT-1 Clinical Study commences
April 5, 2018
NOX raises $10.8 M to advance clinical program
March 22, 2018
Evidence of Abscopal Responses in Patients
March 20, 2018
NOX Reports NOX66 Clinical Data
March 5, 2018
Appendix 4D and Half Year Accounts
February 22, 2018
NOX closes $4m capital raising for US subsidiary Nyrada Inc
February 15, 2018
NOX receives FY17 R&D Tax Rebate
January 17, 2018
EOY Guidance on 2018 NOX66 Clinical Development Strategy
December 21, 2017
Nyrada Inc Opens Capital Raise - Memorandum Released
November 30, 2017
NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
November 28, 2017
Clarification of Incorrect Information
November 23, 2017
Promising Interim Clinical Data for NOX66
November 19, 2017
1st Patient treated in Lupin Study at St Vincents Hospital
November 15, 2017
UNSW collaboration confirms drug designed for stroke victims
November 2, 2017
Australian NOX66 - Radiotherapy Study Opens
September 26, 2017
Establishment of Nyrada Inc.
September 24, 2017
Positive Clinical Outcomes for NOX66 at ESMO Conference
September 11, 2017
Important Brain Cancer Findings for NOX66 Program
August 29, 2017
Reinstatement to Official Quotation
August 24, 2017
Noxopharm raises $5.5 million to advance clinical program
August 23, 2017
Suspension from Official Quotation
August 22, 2017
Noxopharm provides update on NOX66 Clinical Trial Program
July 5, 2017
Idronoxil data provides hope to treat secondary brain cancer
June 18, 2017
NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
June 4, 2017
St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
May 28, 2017
NOX makes strategic commitment to treatment of rare cancers
May 23, 2017
Market Guidance for Next Six Months
May 1, 2017
NOX Files Patent Application on Smart Idronoxil
April 9, 2017
NOX and Monash Uni Collaboration Receives Federal Grant
March 26, 2017
Noxopharm and UNSW combine on stroke project
March 15, 2017
NOX researching rare Abscopal Response
March 3, 2017
Brain Cancer Study Commences
January 31, 2017
First NOX66 Clinical Trial to Commence
January 30, 2017
Breakthrough in Delivering Idronoxil into Brain
November 22, 2016
Initial Clinic Study Announced and Approved
October 25, 2016
Amendment to Preliminary Final Report
September 30, 2016
Preliminary Final Report
August 31, 2016
Noxopharm to Initiate Radiotherapy Clinical Studies
August 22, 2016
Noxopharm Provides Update on Inaugural Clinical Study
August 9, 2016
ASX Market Release - Admission to Official List
August 8, 2016